

AIDS AND INFECTIOUS DISEASES GROUP

Publications: **46**

Impact Factor: **309.798**

Q1: **22**



PUBLICATIONS

- Aldamiz-Echevarría T, González-García J, Von Wichmann MA, Crespo M, López-Aldeguer J, Quereda C, Téllez MJ, Galindo MJ, Sanz J, Santos I, Guardiola JM, Bellón JM, Montes M, Berenguer J. Association of baseline CD4+cell count and HIV-RNA on sustained virologic response to interferon-ribavirin in HIV/HCV coinfected patients. *Ann Hepatol.* 2015;14(4):464-9. Article. IF: 1.816; Q4.
- Antinori A, Clarke A, Svedhem-Johansson V, Arribas JR, Arenas-Pinto A, Fehr J, Gerstoft J, Horban A, Clotet B, Ripamonti D, Girard PM, Hill AM, Moecklinghoff C. Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues. *AIDS.* 2015;29(14):1811-20. Article. IF: 4.407; Q1.
- Arribas JR, Girard PM, Landman R, Pich J, Mallolas J, Martínez-Rebollar M, Zamora FX, Estrada V, Crespo M, Podzamczer D, Portilla J, Dronda F, Iribarren JA, Domingo P, Pulido F, Montero M, Knobel H, Cabie A, Weiss L, Gatell JM. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. *Lancet Infect Dis.* 2015;15(7):785-92. Article. IF: 21.372; DI.
- Bandera AIR, Fernández CG, Vorlicka K, Burguillo ERB, Pinto PH. Severe folliculitis with secondary impetiginization in the scalp of a woman treated with panitumumab. *Int J Dermatol.* 2015;54(6):E226-9. Article. IF: 1.415; Q3.
- Belinchón I, Vanaclocha F, de la Cueva-Dobao P, Coto-Segura P, Labandeira J, Herranz P, Taberner R, Julia B, Cea-Calvo L, Puig L. Metabolic syndrome in Spanish patients with psoriasis needing systemic therapy: Prevalence and association with cardiovascular disease in PSO-RISK, a cross-sectional study. *J Dermatol Treat.* 2015;26(4):318-25. Article. IF: 1.857; Q2.
- Berenguer J, Polo R, Aldeguer JL, Lozano F, Aguirrebengoa K, Arribas JR, Blanco JR, Boix V, Casado JL, Clotet B, Crespo M, Domingo P, Estrada V, García F, Gatell JM, González-García J, Gutiérrez F, Iribarren JA, Knobel H, Libre JM, Locutura J, López JC, Miro JM, Moreno S, Podzamczer D, Portilla J, Pulido F, Ribera E, Riera M, Rubio R, Santos J, Sanz-Moreno J, Sanz J, Téllez MJ, Tuset M, Rivero A. Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015). *Enferm Infec Micr Cl.* 2015;33(8):544-56. Article. IF: 1.53; Q3.
- Berenguer J, Zamora FX, Aldamiz-Echevarría T, Von Wichmann MA, Crespo M, López-Aldeguer J, Carrero A, Montes M, Quereda C, Téllez MJ, Galindo MJ, Sanz J, Santos I, Guardiola JM, Barros C, Ortega E, Pulido F, Rubio R, Mallolas J, Tural C, Jusdado JJ, Pérez G, Díez C, Álvarez-Pellicer J, Esteban H, Bellón JM, González-García J. Comparison of the prognostic value of liver biopsy and FIB-4 Index in patients coinfected with HIV and Hepatitis C Virus. *Clin Infect Dis.* 2015;60(6):950-8. Article. IF: 8.736; DI.
- Bernardino JI, Mocroft A, Mallon PW, Wallet C, Gerstoft J, Russell C, Reiss P, Katlama C, De Wit S, Richert L, Babiker A, Buno A, Castagna A, Girard PM, Chene G, Raffi F, Arribas JR. Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naïve adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. *Lancet HIV.* 2015;2(11):E464-73. Article. IF: 8.364; DI.



3.3 Infectious Diseases and Immunity Area

- Bernardino JI, Antela A. Efficacy of dolutegravir in treatment-naïve patients. The SPRING-1, SPRING-2, SINGLE and FLAMINGO trials. *Enferm Infec Micr Cl.* 2015;33(Suppl 1):42627. Article. IF: 1.53; Q3.
- Blanco JR, Jarrin I, Martínez A, Siles E, Larrayoz IM, Canuelo A, Gutiérrez F, González-García J, Vidal F, Moreno S. Shorter telomere length predicts poorer immunological recovery in virologically suppressed HIV-1-infected patients treated with combined anti-retroviral therapy. *J AIDS-S Acq Imm Def.* 2015;68(1):21-9. Article. IF: 3.806; Q1.
- Blasco AJ, Llibre JM, Berenguer J, González-García J, Knobel H, Lozano F, Podzamczer D, Pulido F, Rivero A, Tuset M, Lázaro P, Gatell JM. Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. *Enferm Infec Micr Cl.* 2015;33(3):156-65. Article. IF: 1.53; Q3.
- Blázquez D, Ramos-Amador JT, Sainz T, Mellado MJ, García-Ascaso M, de José MI, Rojo P, Navarro ML, Muñoz-Fernández MA, Saavedra J, Roa MA, Jiménez S, Beceiro J, Prieto L, Hortelano MG, González-Tome MI. Lipid and glucose alterations in perinatally-acquired HIV-infected adolescents and young adults. *BMC Infect Dis.* 2015;15:119. Article. IF: 2.69; Q2.
- Briz V, Sepúlveda-Crespo D, Diniz AR, Borrego P, Rodés B, de la Mata FJ, Gómez R, Taveira N, Muñoz-Fernández MA. Development of water-soluble polyanionic carbosilane dendrimers as novel and highly potent topical anti-HIV-2 microbicides. *Nanoscale.* 2015;7(35):14669-83. Article. IF: 7.76; DI.
- Cain LE, Phillips A, Olson A, Sabin C, José S, Justice A, Tate J, Logan R, Robins JM, Sterne JAC, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernan MA, (González J, Bernardino I, Arribas JR, Montes ML, Peña JM, Arribas B, Castro JM, Zamora FJ, Pérez I, Estébanez M.). Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-infected individuals in high-income countries. *Clin Infect Dis.* 2015;60(8):1262-8. Article. IF: 8.736; DI.
- Calleja JL, Pascasio JM, Ruiz-Antorán B, Gea F, Barcena R, Larrubia JR, Pérez-Álvarez R, Sousa JM, Romero-Gómez M, Sola R, de la Revilla J, Crespo J, Navarro JM, Arenas JL, Delgado M, Fernández-Rodríguez CM, Planas R, Buti M, Forns X. Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis. *Liver Int.* 2015;35(1):90-100. Article. IF: 4.47; Q1.
- Carr A, Grund B, Neuhaus J, Schwartz A, Bernardino JI, White D, Badel-Faesen S, Avihingsanon A, Ensrud K, Hoy J. Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of Anti-Retroviral Treatment (START) trial. *HIV Med.* 2015;16:137-46. Article. IF: 3.341; Q2.
- Casado JL, Abad-Fernández M, Moreno S, Pérez-Elías MJ, Moreno A, Bernardino JI, Vallejo A. Visceral leishmaniasis as an independent cause of high immune activation, T-cell senescence, and lack of immune recovery in virologically suppressed HIV-1-coinfected patients. *HIV Med.* 2015;16(4):240-8. Article. IF: 3.341; Q2.
- Castells L, Rimola A, Manzardo C, Valdiveo A, Montero JL, Barcena R, Abradelo M, Xiol X, Aguilera V, Salcedo M, Rodríguez M, Bernal C, Suárez F, Antela A, Olivares S, del Campo S, Laguno M, Fernández JR, de la Rosa G, Aguero F, Pérez I, González-García J, Esteban-Mur JI, Miro JM. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: A prospective cohort study. *J Hepatol.* 2015;62(1):92-100. Article. IF: 10.59; DI.
- Cedillo JL, Arnalich F, Martín-Sánchez C, Quesada A, Ríos JJ, Maldifassi MC, Atienza G, Renart J, Fernández-Capitán C, García-Río F, López-Collazo E, Montiel C. Usefulness of alpha 7 nicotinic receptor messenger RNA levels in peripheral blood mononuclear cells as a marker for cholinergic antiinflammatory pathway activity in septic patients: Results of a Pilot Study. *J Infect Dis.* 2015;211(1):146-155. Article. IF: 6.344; DI.
- Curran A, Pérez-Valero I, Molto J. Rezoista (R) (Darunavir/Cobicistat): First boosted protease inhibitor co-formulated with cobicistat. *Aids Rev.* 2015;17(2):114-20. Review. IF: 2.068; Q3.
- Díaz A, Ten A, Marcos H, Gutiérrez G, González-García J, Moreno S, Barrios AM, Arponeni S, Portillo A, Serrano R, García MT, Pérez JL, Toledo J, Royo MC, González G, Izquierdo A, Viloria LJ, López I, Elizalde L, Martínez E, Castrillejo D, Aranguren R, Redondo C, Díez M. Factors determining irregular attendance to follow-up visits among human immunodeficiency virus patients: Results of the hospital survey of patients infected with human immunodeficiency virus. *Enferm Infec Micr Cl.* 2015;33(5):324-30. Article. IF: 1.53; Q3.
- Estrada V, Bernardino JI, Masia M, Iribarren JA, Ortega A, Lozano F, Miralles C, Olalla J, Santos J, Elías MJP, Domingo P, Cruz AF. Cardiovascular risk factors and lifetime risk estimation in HIV-infected patients under antiretroviral treatment in Spain. *HIV Clin Trials.* 2015;16(2):57-65. Article. IF: 1.951; Q1.
- Gathe J, Arribas JR, Van Lunzen J, Garner W, Speck RM, Bender R, Shreay S, Nguyen T. Patient-reported symptoms over 48 weeks in a randomized, open-label, phase 3b non-inferiority trial of adults with HIV Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir DF versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir DF. *Patient.* 2015;8(5):445-54. Article. IF: 2.227; Q2.
- González-Munera A, García-Fernández ME, Ríos-Blanco JJ. Sarcoidosis-lymphoma syndrome. *Med Clin-Barcelona.* 2015;145(6):277-8. Letter. IF: 1.267; Q2.
- González-Ramos J, Alonso-Pacheco M L, Mayor-Ibarguren A, Herranz-Pinto P. Gastric mucosa-associated lymphoid tissue lymphoma in a patient with severe psoriasis receiving ustekinumab. *Actas Dermosifiliogr.* 2015;106(4):326. Letter. Not indexed.

- Ibarguren AM, Fernández CG, Barranco AT, Fournier MF, Ramos JG, Gómez MPR, Pinto PH. Herpes zoster: a potential risk associated with fingolimod treatment. *Int J Dermatol.* 2015;54(9):E373-5. Letter. IF: 1.415; Q3.
- Lundgren D, Babiker AG, Gordin F, Emery S, Sharma S, Avihingsanon AC, Cooper DA, Tkenheuer GF, Llibre JM, Molina JM, Munduri P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD, (Arribas JR). Initiation of antiretroviral therapy in early asymptomatic HIV infection. *New Engl J Med.* 2015;373(9):795-807. Article. IF: 59.558; DI.
- Martínez E, González-Cordón A, Ferrer E, Domingo P, Negredo E, Gutiérrez F, Portilla J, Curran A, Podzamczer D, Ribera E, Murillas J, Bernardino JI, Santos I, Carton JA, Peraire J, Pich J, Deulofeu R, Pérez I, Gatell JM. Differential body composition effects of protease inhibitors recommended for initial treatment of HIV Infection: A randomized clinical trial. *Clin Infect Dis.* 2015;60(5):811-20. Article. IF: 8.736; DI.
- Mayor Ibarguren A, González Ramos J, Beato Merino M, Maseda Pedrero R, Gómez Fernández C, Herranz Pinto P. Vascular tumor on the forehead of an HIV Patient. *Indian J Dermatol.* 2015;60(4):42. Article. Not indexed.
- Mayor-Ibarguren A, Gómez-Fernández C, Beato-Merino MJ, González-Ramos J, Rodríguez-Bandera AI, Herranz-Pinto P. Diffuse reactive angioendotheliomatosis secondary to the administration of trabectedin and pegfilgrastim. *Am J Dermatopathol.* 2015;37(7):581-4. Article. IF: 1.396; Q3.
- Molina JM, Orkin C, Iser DM, Zamora FX, Nelson M, Stephan C, Massetto B, Gaggar A, Ni L, Svarovskaia E, Brainard D, Subramanian GM, McHutchison JG, Puoti M, Rockstroh JK. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. *Lancet.* 2015;385(9973):1098-106. Article. IF: 44.002; DI.
- Monge S, Díez M, Álvarez M, Guillot V, Iribarren JA, Palacios R, Delgado R, Jaen A, Blanco JR, Domingo P, Portilla J, Pérez Elias M J, García F. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012). *Clin Microbiol Infec.* 2015;21(1):105.e1. Article. IF: 4.575; Q1.
- Mora-Rillo M, Arsuaga M, Ramírez-Olivencia G, de la Calle F, Borobia AM, Sánchez-Seco P, Lago M, Figueira JC, Fernández-Puntero B, Viejo A, Negredo A, Núñez C, Flores E, Carcas AJ, Jiménez-Yuste V, Lasala F, García-de-Lorenzo A, Arnalich F, Arribas JR. Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain. *Lancet Resp Med.* 2015;3(7):554-62. Article. IF: 15.328; DI.
- Mora-Rillo M, Fernández-Romero N, Navarro-San Francisco C, Díez-Sebastian J, Romero-Gómez MP, Fernández FA, López JRA, Mingorance J. Impact of virulence genes on sepsis severity and survival in *Escherichia coli* bacteremia. *Virulence.* 2015;6(1):93-100. Article. IF: 5.418; DI.
- Pardo JRP, García VP. Infectious spondylitis: 30 years later, problems persist. Should we change the approach? *Rev Clin Esp.* 2015;215(5):272-3. Editorial Material. IF: 0.76; Q3.
- Pérez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera M, Estebáñez M, Santos J, Sanz-Moreno J, Troya J, Marino A, Antela A, Navarro J, Esteban H, Moreno S. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. *Lancet Infect Dis.* 2015;15(7):775-84. Article. IF: 21.372; DI.
- Pérez-Valero I, Arribas JR. Second-line antiretroviral therapy and the human factor. *Lancet HIV.* 2015;2(2):E34-5. Editorial Material. IF: 8.364; DI.
- Rodríguez-Bano J, Cisneros JM, Cobos-Trigueros N, Fresco G, Navarro-San Francisco C, Gudiol C, Horcajada JP, López-Cerero L, Martínez JA, Molina J, Montero M, Paño-Pardo JR, Pascual A, Peña C, Pintado V, Retamar P, Tomás M, Borges-Sa M, Garnacho-Montero J, Bou G. Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology. *Enferm Infec Micr Cl.* 2015;33(5):337. Article. IF: 1.53; Q3.
- Rodríguez-Bano J, Cisneros JM, Cobos-Trigueros N, Fresco G, Navarro-San Francisco C, Gudiol C, Horcajada JP, López-Cerero L, Martínez JA, Molina J, Montero M, Pano-Pardo JR, Pascual A, Peña C, Pintado V, Retamar P, Tomás M, Borges-Sa M, Garnacho-Montero J, Bou G. Executive summary of the diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). *Enferm Infec Micr Cl.* 2015;33(5):338-41. Article. IF: 1.53; Q3.
- Romero-Gómez M, Turnes J, Ampuero J, Oyáquez I, Cuenca B, González-García J, Muñoz-Molina B, Aguilar R, Leal S, Planas R, García-Samaniego J, Diago M, Crespo J, Calleja JL, Casado MA, Sola R. Prediction of week 4 virological response in hepatitis C for making decision on triple therapy: The Optim Study. *Plos One.* 2015;10(3):e0122613. Article. IF: 3.057; Q1.
- Sáez-Comet L, Simeón-Aznar CP, Pérez-Conesa M, Vallejo-Rodríguez C, Tolosa-Vilella C, Iniesta-Arandía N, Colunga-Arguelles D, Egurbide-Arberas MV, Ortego-Centeno N, Vargas-Hitos JA, Freire-Dapena M, Rubio-Rivas M, Ríos-Blanco JJ, Trapiella-Martínez L, Fonollosa-Pla V. Applying the ACR/EULAR systemic sclerosis classification criteria to the Spanish Scleroderma Registry Cohort. *J Rheumatol.* 2015;42(12):2327-31. Article. IF: 3.236; Q2.
- Sainz T, Álvarez-Fuente M, Fernández-Jiménez R, González-Tome MI, de José MI, Ramos JT, Navarro ML, Martínez J, García-Hortelano M, Medrano C, Muñoz-Fernández MA, Mellado MJ. Cardiac function in vertically HIV-infected children and adolescents in



3.3 Infectious Diseases and Immunity Area

the era of highly active antiretroviral therapy. *Pediatr Infect Dis J.* 2015;34(5):E125-31. Article. IF: 2.587; Q1.

- Sánchez-Recalde A, Alcolea S, Ríos-Blanco JJ. Optical coherence tomography in thromboembolic pulmonary hypertension. *Rev Esp Cardiol (Engl Ed).* 2015;68(5):437. Article. Not indexed.
- Sendagorta E, Romero MP, Bernardino JL, Beato MJ, Álvarez-Gallego M, Herranz P. Human papillomavirus mRNA testing for the detection of anal high-grade squamous intraepithelial lesions in men who have sex with men infected with HIV. *J Med Virol.* 2015;87(8):1397-403. Article. IF: 1.998; Q3.
- Simeón-Aznar CP, Fonollosa-Pla V, Tolosa-Vilella C, Espinosa-Garriga G, Campillo-Grau M, Ramos-Casals M, García-Hernandez FJ, Castillo-Palma MJ, Sánchez-Román J, Callejas-Rubio JL, Ortego-Centeno N, Egurbide-Arberas MV, Trapiella-Martínez L, Caminal-Montero L, Saez-Comet L, Velilla-Marco J, Camps-García MT, de Ramón-Garrido E, Esteban-Marcos EM, Pallares-Ferrer L, Navarrete-Navarrete N, Vargas-Hitos JA, de la Torre RG, Salvador-Cervello G, Ríos-Blanco JJ, Vilardell-Tarres M. Registry of the Spanish Network for Systemic Sclerosis Survival, prognostic factors, and causes of death. *Medicine.* 2015;94(43):e1728. Article. IF: 2.133; Q2.
- Yazdanpanah Y, Arribas JR, Malvy D. Treatment of Ebola virus disease. *Intens Care Med.* 2015;41(1):115-7. Editorial Material. IF: 10.125; DI.